Aurobindo Receives FDA Approval for Prednisolone Tablets USP, 5 mg
Published: March 17, 2023
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Prednisolone Tablets USP, 5 mg. Aurobindo Pharma’s Prednisolone Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Prednisolone Tablets manufactured by Watson Laboratories Inc.
Prednisolone Tablets are indicated in the following conditions:
- Endocrine disorders
- Rheumatic disorders
- Collagen diseases
- Dermatologic diseases
- Allergic states
- Ophthalmic diseases
- Respiratory diseases
- Hematologic disorders
- Neoplastic diseases
- Edematous states
- Gastrointestinal diseases
- Nervous system
- Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy; trichinosis with neurologic or myocardial involvement.